R&D Pipeline

 

Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.

 

Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.

Neurodegenerative Diseases

Target
Indication
Drug Candidate

c-Abl

Parkinson, ALS

FB-101 / Discovery

c-Abl/LRRK2

ALS, Parkinson

FB-418 / Discovery

c-Abl/PET

PET tracer for c-Abl therapeutic

1ST-102-PET / Discovery

Undisclosed

Parkinson, Alzheimer, ALS

1ST-103 / Discovery

Undisclosed

Parkinson

1ST-105 / Discovery
Discovery
Preclinical
Phase 1

Oncology

Target
Indication
Drug Candidate

HPK1

Immuno-oncology

1ST-201 / Discovery

Undisclosed

AI-driven drug discovery for glioblastoma

1ST-205 / Discovery
Discovery
Preclinical
Phase 1

Rare Diseases

Target
Indication
Drug Candidate

Undisclosed

Rett syndrome and other genetic diseases

1ST-301 / Discovery
Discovery
Preclinical
Phase 1

Platform Technology

Platform
description
Partner

GeniFiNDTM
1ST-401

Genomic-based target discovery platform for neurodegenerative diseases